Modificare „BioNTech schimba directia”

<p>Venituri totale in 2022: 17.3 mld. EUR, in [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Financial%20Review%20for%20the%20Fourth%20Quarter%20and%20Full%20Year%202022%20Financial%20Results scadere] cu 9% vs anul precedent.</p><p>Profit net in 2022: 9.43 mld. EUR, in [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Financial%20Review%20for%20the%20Fourth%20Quarter%20and%20Full%20Year%202022%20Financial%20Results scadere] cu 8% vs anul precedent.</p><p>EPS in [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Financial%20Review%20for%20the%20Fourth%20Quarter%20and%20Full%20Year%202022%20Financial%20Results 2022]: 37.77 EUR pe actiune (vs 39.63 EUR pe actiune in anul precedent).</p><p>Pentru 2023, BioNTech [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Outlook%20for%20the%202023%20Financial%20Year%3A se asteapta] la venituri totale substantial mai mici, de circa 5 mld. EUR, sub [https://www.biopharma-reporter.com/Article/2023/03/27/BioNTech-s-COVID-19-vaccine-revenue-forecasts-lower-than-expected#:~:text=Lee%20Brown%2C%20global,said%20the%20analyst. asteptarile] analistilor. Cu ocazia publicarii rezultatelor si a estimarilor financiare azi, compania germana [https://investors.biontech.de/news-releases/news-release-details/biontech-announces-fourth-quarter-and-full-year-2022-financial#:~:text=Outlook%20for%20the%202023%20Financial%20Year%3A a anuntat]&nbsp;ca renegociaza contractul pe care il are cu Comisia Europeana privind furnizarea propriului vaccin anti-Covid, dezvoltat in colaborare cu Pfizer. Discutiile ar putea avea ca rezultat o reducere a vanzarilor imediate, pe seama extinderii livrarilor pe mai multi ani.</p><p>Tot pentru 2023, BioNTech [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=In%20a%20statement%20on%20Monday%2C%20Germany%27s%20BioNTech%20(22UAy.DE)%2C%20Pfizer%27s%20(PFE.N)%20partner%20on%20the%20Comirnaty%20vaccine%2C%20said%20it%20plans%20to%20spend%202.4%20to%202.6%20billion%20euros%20on%20research%20and%20development%20(R%26D)%20in%202023%2C%20up%20from%201.54%20billion%20euros%20last%20year. isi propune] sa cheltuiasca pana la 2.6 mld. EUR pentru cercetare si dezvoltare, comparativ cu 1.54 mld. EUR anul trecut. Compania [https://www.theguardian.com/society/2022/oct/16/vaccines-to-treat-cancer-possible-by-2030-say-biontech-founders se reorienteaza] catre dezvoltarea unor tratamente revolutionare contra afectiunilor oncologice, [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=It%20will%20also,2023%20and%202024. afirmand] ca, pentru unele dintre acestea, va cere avizul agentiilor de reglementare chiar pe parcursul acestui an si in 2024. La finalul anului 2022, BioNTech [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=Thanks%20to%20its%20COVID%2Dvaccine%20market%20lead%20in%20the%20Western%20world%2C%20BioNTech%20ended%20the%20year%202022%20with%20a%20cash%20balance%20of%2013.9%20billion%20euros%20plus%20receivables%2C%20or%20cash%20it%20stands%20to%20receive%2C%20of%207.14%20billion%20euros. avea] lichiditati de 13.9 mld. EUR si creante de 7.14 mld. EUR.</p><p>BioNTech [https://www.reuters.com/business/healthcare-pharmaceuticals/cash-rich-biontech-plans-spend-about-1-bln-more-research-this-year-2023-03-27/#:~:text=The%20company%20said%20it%20expects%20to%20authorise%20new%20share%20buybacks%20worth%20up%20to%20%24500%20million%20this%20year%2C%20having%20already%20spent%20%241.3%20billion%20on%20own%20shares%20through%20March%2017. a mai indicat] azi ca va derula un nou program de buybacks, prin care isi va rascumpa actiuni proprii in valoare de pana la 500 mil. EUR pana la finalul acestui an. Pana acum, cheltuielile cu buybacks s-au ridicat la 1.3 mld. EUR.</p><p>BioNTech [https://www.reuters.com/article/us-biontech-ipo-idUSKBN1WO29B s-a listat] pe bursa americana, la NASDAQ, in octombrie 2019, la pretul de 10 USD pe actiune. In aceasta dupa-amiaza, compania se tranzactiona la circa 122 USD pe actiune, marcand o pierdere de 28% in ultimele 12 luni.</p><p>(US.BNTX)</p>
[[Categorie:US.BNTX]][[Categorie:Analize]][[Categorie:Stiri despre piata]]
{{DEFAULTSORT:-2023-03-27}}